<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The deregulation of the DNA damage response (DDR) can contribute to <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> and favor the progression from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Since hypomethylating agent, notably <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, constitute an efficient therapy for patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we assessed whether such compounds can activate the DDR in malignant blasts </plain></SENT>
<SENT sid="2" pm="."><plain>While <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> had moderate effects on <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle progression, both agents induced profound changes in the expression and functionality of DDR-related proteins </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi>, and to a lesser degree <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, induced the activation of checkpoint kinases Chk-1 and Chk-2 and the phosphorylation of the DDR-sensor H2AX </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, hypomethylating agents were found to cause the dephosphorylation of the transcriptional regulator forkhead box O3, best known as FOXO3A, whose phosphorylation has been related to poor prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The dephoasphorylation of FOXO3A induced by <z:chebi fb="0" ids="2038">azacitidine</z:chebi> or <z:chebi fb="0" ids="50131">decitabine</z:chebi> in malignant blasts was accompanied by the translocation of FOXO3A from the cytoplasm to the nucleus </plain></SENT>
<SENT sid="6" pm="."><plain>Upon stimulation with <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-derived, <z:chebi fb="0" ids="2038">azacitidine</z:chebi>-sensitive SKM-1S cells upregulated FOXO3A and the pro-apoptotic FOXO3A targets BIM and PUMA, and this effect was attenuated or abolished in <z:chebi fb="0" ids="2038">azacitidine</z:chebi>-resistant SMK-1R cells </plain></SENT>
<SENT sid="7" pm="."><plain>Altogether, our results suggest that the reactivation of FOXO3A may contribute to the effects of hypomethylating agents in malignant blasts </plain></SENT>
</text></document>